Placenta study aims to unlock drug safety in pregnancy

NCT ID NCT04400084

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study uses placentas donated after childbirth to measure how drugs pass from mother to fetus. Researchers will perfuse the placenta in a lab to calculate drug transfer rates. The goal is to fill a gap in knowledge about medication safety during pregnancy, since pregnant women are often excluded from drug trials. Up to 2,000 women with normal pregnancies will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors understand which drugs are safe during pregnancy and how they affect the fetus.

What could go wrong

This is an ex vivo lab study using placentas after birth, not a treatment trial. Results may not fully predict real-life drug effects in pregnant women.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NORMAL PREGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CIC Port-Royal-Cochin

    RECRUITING

    Paris, 75014, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••